Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD1 | P21728 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ESR1 | P03372 | 2/20 | 0.31 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29663718 | 1.00 | DRD1 (0.42) | DRD1CYP3A4TDP1MEN1CYP2C9 | |
| SCHEMBL15222147 | 0.92 | DRD1 (0.38) | DRD1CYP3A4TDP1MEN1KMT2A | |
| SCHEMBL15268226 | 0.91 | DRD1 (0.40) | DRD1CYP3A4TDP1 | |
| SCHEMBL29638087 | 0.90 | DRD1 (0.45) | DRD1CYP3A4TDP1CYP2C9SIGMAR1 | |
| SCHEMBL31084186 | 0.87 | DRD1 (0.35) | DRD1TDP1 | |
| SCHEMBL17758768 | 0.87 | DRD1 (0.35) | DRD1 | |
| SCHEMBL31084193 | 0.87 | DRD1 (0.35) | DRD1TDP1 | |
| SCHEMBL15866604 | 0.87 | DRD1 (0.38) | DRD1 | |
| SCHEMBL10016849 | 0.85 | DRD1 (0.38) | DRD1CYP3A4TDP1CYP2C9ESR1 | |
| SCHEMBL18788587 | 0.85 | DRD1 (0.33) | DRD1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022127320-A1 | INTERMEDIATE, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 四川大学 | 2022-06-23 | — | — | WO | claimed |
| EP-4702000-A1 | ALKYLATION PROCESS | University of Liverpool (GB) | 2026-03-04 | — | — | EP | disclosed |
| WO-2024224034-A1 | ALKYLATION PROCESS | THE UNIVERSITY OF LIVERPOOL (GB) | 2024-10-31 | — | — | WO | disclosed |
| EP-3995492-B1 | A TWO-STEP PROCESS FOR PREPARING 3-SUBSTITUTED PHENYLALKYLAMINES | SpecGx LLC (US) | 2024-05-29 | — | — | EP | disclosed |
| CN-116023382-A | Method for synthesizing chiral tetrahydropyrazolo [1,5-a ] pyrimidine | 北京师范大学 | 2023-04-28 | — | — | CN | disclosed |
| EP-3166923-B1 | PROCESS FOR PREPARING SUBSTITUTED PHENYLALKANES | SpecGx LLC (US) | 2023-03-15 | — | — | EP | disclosed |
| US-11530230-B2 | Compound of 3,3,3′,3′-tetramethyl-1,1′-spirobiindane-based phosphine ligand, and preparation method thereof | ZHEJIANG UNIVERSITY (CN) | 2022-12-20 | — | — | US | disclosed |
| US-11530230-B2 | Compound of 3,3,3′,3′-tetramethyl-1,1′-spirobiindane-based phosphine ligand, and preparation method thereof | ZHEJIANG UNIVERSITY (CN) | 2022-12-20 | — | — | US | disclosed |
| WO-2022127320-A1 | INTERMEDIATE, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 四川大学 | 2022-06-23 | — | — | WO | disclosed |
| EP-3995492-A1 | A TWO-STEP PROCESS FOR PREPARING 3-SUBSTITUTED PHENYLALKYLAMINES | SpecGx LLC (US) | 2022-05-11 | — | — | EP | disclosed |
| US-20140187809-A1 | NOVEL RUTHENIUM COMPLEX AND PROCESS FOR PRODUCING OPTICALLY ACTIVE ALCOHOL COMPOUND USING SAME AS CATALYST | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2014-07-03 | — | — | US | disclosed |
| EP-2609071-A1 | NEW PROCESS FOR THE PREPARATION OF INTERMEDIATES USEFUL FOR THE MANUFACTURE NEP INHIBITORS | Novartis AG (CH) | 2013-07-03 | — | — | EP | disclosed |
| US-20130158275-A1 | NEW PROCESS FOR THE PREPARATION OF INTERMEDIATES USEFUL FOR THE MANUFACTURE NEP INHIBITORS | NOVARTIS AG (CH) | 2013-06-20 | — | — | US | disclosed |
| US-20130041151-A1 | RUTHENIUM COMPLEX AND METHOD FOR PREPARING OPTICALLY ACTIVE ALCOHOL COMPOUND | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2013-02-14 | — | — | US | disclosed |
| WO-2012025502-A1 | NEW PROCESS FOR THE PREPARATION OF INTERMEDIATES USEFUL FOR THE MANUFACTURE NEP INHIBITORS | NOVARTIS AG (CH) | 2012-03-01 | — | — | WO | disclosed |
| US-7714149-B2 | Chiral spiro compounds and their use in asymmetric catalytic reactions | THE PENN STATE RESEARCH FOUNDATION (US) | 2010-05-11 | — | — | US | disclosed |
| US-7714149-B2 | Chiral spiro compounds and their use in asymmetric catalytic reactions | THE PENN STATE RESEARCH FOUNDATION (US) | 2010-05-11 | — | — | US | disclosed |
| US-7589218-B2 | Chiral spiro compounds and their use in asymmetric catalytic reactions | THE PENN STATE RESEARCH FOUNDATION (US) | 2009-09-15 | — | — | US | disclosed |
| US-7589218-B2 | Chiral spiro compounds and their use in asymmetric catalytic reactions | THE PENN STATE RESEARCH FOUNDATION (US) | 2009-09-15 | — | — | US | disclosed |
| US-20080293953-A1 | Chiral spiro compounds and their use in asymmetric catalytic reactions | THE PENN STATE RESEARCH FOUNDATION (US) | 2008-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158275-A1 | NEW PROCESS FOR THE PREPARATION OF INTERMEDIATES USEFUL FOR THE MANUFACTURE NEP INHIBITORS | MME, DNPEP, REN | DRD1 3327/4885CYP3A4 213/4885TDP1 1410/4885 |
| US-20080293953-A1 | Chiral spiro compounds and their use in asymmetric catalytic reactions | NCOR2, NCOR1, NCOA2 | DRD1 923/4885CYP3A4 254/4885TDP1 4656/4885 |
| US-20130041151-A1 | RUTHENIUM COMPLEX AND METHOD FOR PREPARING OPTICALLY ACTIVE ALCOHOL COMPOUND | ADH5, ADH1C, ADH1A | DRD1 121/4885CYP3A4 20/4885TDP1 4056/4885 |
| US-20140187809-A1 | NOVEL RUTHENIUM COMPLEX AND PROCESS FOR PRODUCING OPTICALLY ACTIVE ALCOHOL COMPOUND USING SAME AS CATALYST | ADH1C, ADH5, ADH1A | DRD1 117/4885CYP3A4 31/4885TDP1 4367/4885 |
| US-11530230-B2 | Compound of 3,3,3′,3′-tetramethyl-1,1′-spirobiindane-based phosphine ligand, and preparation method thereof | ORMDL3, TALDO1, TAC3 | DRD1 271/4885CYP3A4 1674/4885TDP1 3979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.